4-methoxy-1-methylpiperidine | 90633-24-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-methoxy-1-methylpiperidine
• CAS: 90633-24-2
• 化学式: C₇H₁₅NO
• 分子量: 129.202
• InChiKey: YZMIRCBSCFJIFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-甲氧基吡啶 在 platinum(IV) oxide 氢气 作用下， 以 甲醇 、 乙腈 为溶剂， 20.0~30.0 ℃ 、101.33 kPa 条件下， 反应 72.0h， 生成 4-methoxy-1-methylpiperidine
  参考文献：
  名称：

  Bailey, Judith M.; Booth, Harold; Al-Shirayda, Hatif A.R.Y., Journal of the Chemical Society. Perkin transactions II, 1984, p. 737 - 744

  摘要：

  DOI：

文献信息

• NOVEL COMPOUNDS
  申请人：GRAUERT Matthias

  公开号：US20130184248A1

  公开（公告）日：2013-07-18

  This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R 1 , R 2 , R 3 have meanings given in the description.

  这项发明涉及到式I的化合物，它们作为mGlu5受体活性的正向变构调节剂的用途，含有这些化合物的药物组合物，以及将其用作治疗和/或预防与谷氨酸功能障碍相关的神经和精神疾病，如精神分裂症或认知功能下降，如痴呆症或认知障碍的药剂的方法。A、B、Ar、R1、R2、R3在描述中有给定的含义。
• Photochromic Indeno-Fused Ring Pyran Compounds
  申请人：Transitions Optical, Inc.

  公开号：US20150141661A1

  公开（公告）日：2015-05-21

  The present invention relates to photochromic indeno-fused ring pyran compounds represented by the following Formula (I-A): The present invention also relates to photochromic dichroic compounds, such as represented by Formula (I-A), in which (i) Z 2 is a group N—R 13 in which R 13 is a group L, and (ii) optionally at least one R 1 independently for each n is selected from a group L, in which the group L independently in each case is a lengthening group that provides the photochromic compound with dichroic properties, in accordance with some embodiments. The present invention also relates to photochromic articles, such as photochromic ophthalmic articles, that include one or more photochromic compounds according to the present invention, such as represented by Formula (I-A).

  本发明涉及由以下式（I-A）表示的光致变色吲哚融合环吡喃化合物。本发明还涉及光致二向色化合物，例如由式（I-A）表示，其中（i）Z2是一个N—R13基团，其中R13是一个L基团，以及（ii）对于每个n，可选地至少选择一个R1，每种情况下独立选择自L基团，其中每种情况下L基团是一个提供光致化合物二向色性能的延伸基团，符合某些实施例。本发明还涉及光致物品，例如光致眼科物品，包括根据本发明的一个或多个光致化合物，例如由式（I-A）表示。
• [EN] PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS.<br/>[FR] DÉRIVÉS DE PYRIMIDINE, PYRIDINE ET TRIAZINE EN TANT QU'OUVREURS DE CANAUX MAXI-K
  申请人：MITSUBISHI TANABE PHARMA CORP

  公开号：WO2009125870A1

  公开（公告）日：2009-10-15

  A compound of formula (A); wherein ring A is an aromatic ring or a heteroaromatic ring; R1 is independently halogen, cyano, etc., each of X1, X2 and X3 is CR2 or nitrogen, R2 is independently hydrogen, etc., n is 0, 1, 2, 3 or 4; -D-Y is -O-CH2COOH, etc, and G is a substituted amino, a substituted heterocyclic group, etc, or a pharmaceutical acceptable salt thereof, has activities of opening BK channels.

  化合物的结构式（A）；其中环A是芳香环或杂芳环；R1独立地是卤素、氰基等；X1、X2和X3中的每一个是CR2或氮，R2独立地是氢等；n为0、1、2、3或4；-D-Y是-O-CH2COOH等；G是取代氨基、取代杂环基等，或其药用可接受盐，具有开放BK通道的活性。
• [EN] 1-(DIHYDRONAPHTHALENYL)PYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS<br/>[FR] 1-(DIHYDRONAPHTALÉNYL)PYRIDONES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR 1 DE L'HORMONE DE CONCENTRATION DE LA MÉLANINE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2013149362A1

  公开（公告）日：2013-10-10

  Provided are 1-(dihydronaphthalenyl)pyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy for the treatment of obesity and diabetes.

  提供的是1-(二氢萘基)吡啶酮，它们是黑素浓集激素受体1（MCHR1）的拮抗剂，包含它们的药物组合物，它们的制备过程，以及它们在治疗肥胖和糖尿病方面的用途。
• [EN] 2 -AMINOBENZ IMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION<br/>[FR] DÉRIVÉS DE 2-AMINO-BENZIMIDAZOLE UTILES DANS LE TRAITEMENT D'INFLAMMATION
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012076672A1

  公开（公告）日：2012-06-14

  This invention relates to compounds of formula (I), their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the 10 treatment and/or prevention of inflammatory diseases and associated conditions. A, M, W, R1, R2, R3, R4, R6, R2,R7, R8, R9, Ra, Rb have meanings given in the description.

  本发明涉及公式（I）的化合物，它们作为微体前列腺素E2合酶-1（mPGES-1）的抑制剂的使用，包含它们的药物组合物，以及它们作为治疗和/或预防炎症性疾病及相关状况的药物的使用。A、M、W、R1、R2、R3、R4、R6、R2、R7、R8、R9、Ra、Rb的含义在描述中给出。